

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Update on GH therapy in adults | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-2017/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-2017" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Update on GH therapy in adults" />
    
            <meta name="og:title" content="F1000Research Article: Update on GH therapy in adults.">
            <meta name="og:description" content="Read the latest article version by Cesar Luiz Boguszewski, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="13044">
            <meta name="article-id" content="12057">
            <meta name="dc.title" content="Update on GH therapy in adults">
            <meta name="dc.description" content="Over the last three decades, short- and long-term observational studies, clinical trials, systematic reviews, and meta-analyses have provided relevant information on the efficacy and safety of growth hormone (GH) replacement therapy in adults with GH deficiency (AGHD). The knowledge acquired during this time has been compiled into different guidelines that offer clinicians an evidence-based, practical approach for the management of AGHD. There are, however, still open questions in some key areas in which recommendations are supported by only moderate or weak evidence. In the last recent years, the development of long-acting GH preparations has created new therapeutic possibilities by decreasing injection frequency, improving adherence and thereby potentially maximizing clinical outcomes. The aims of this review are to advance our understanding on the diagnosis and treatment of AGHD and to present an update and future perspectives on the use of long-acting GH preparations.">
            <meta name="dc.subject" content="growth hormone,adults with GH deficiency,IGF-I">
            <meta name="dc.creator" content="Boguszewski, Cesar Luiz">
            <meta name="dc.date" content="2017/11/16">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.12057.1">
            <meta name="dc.source" content="F1000Research 2017 6:2017">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="growth hormone">
            <meta name="prism.keyword" content="adults with GH deficiency">
            <meta name="prism.keyword" content="IGF-I">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/11/16">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="2017">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.12057.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-2017">
            <meta name="citation_title" content="Update on GH therapy in adults">
            <meta name="citation_abstract" content="Over the last three decades, short- and long-term observational studies, clinical trials, systematic reviews, and meta-analyses have provided relevant information on the efficacy and safety of growth hormone (GH) replacement therapy in adults with GH deficiency (AGHD). The knowledge acquired during this time has been compiled into different guidelines that offer clinicians an evidence-based, practical approach for the management of AGHD. There are, however, still open questions in some key areas in which recommendations are supported by only moderate or weak evidence. In the last recent years, the development of long-acting GH preparations has created new therapeutic possibilities by decreasing injection frequency, improving adherence and thereby potentially maximizing clinical outcomes. The aims of this review are to advance our understanding on the diagnosis and treatment of AGHD and to present an update and future perspectives on the use of long-acting GH preparations.">
            <meta name="citation_description" content="Over the last three decades, short- and long-term observational studies, clinical trials, systematic reviews, and meta-analyses have provided relevant information on the efficacy and safety of growth hormone (GH) replacement therapy in adults with GH deficiency (AGHD). The knowledge acquired during this time has been compiled into different guidelines that offer clinicians an evidence-based, practical approach for the management of AGHD. There are, however, still open questions in some key areas in which recommendations are supported by only moderate or weak evidence. In the last recent years, the development of long-acting GH preparations has created new therapeutic possibilities by decreasing injection frequency, improving adherence and thereby potentially maximizing clinical outcomes. The aims of this review are to advance our understanding on the diagnosis and treatment of AGHD and to present an update and future perspectives on the use of long-acting GH preparations.">
            <meta name="citation_keywords" content="growth hormone,adults with GH deficiency,IGF-I">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Cesar Luiz Boguszewski">
            <meta name="citation_author_institution" content="Endocrine Division (SEMPR), Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil">
            <meta name="citation_publication_date" content="2017/11/16">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="2017">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.12057.1">
            <meta name="citation_firstpage" content="2017">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-2017/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-2017.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=13044 /> <input type=hidden id=articleId name=articleId value=12057 /> <input type=hidden id=xmlUrl value="/articles/6-2017/v1/xml"/> <input type=hidden id=xmlFileName value="-6-2017-v1.xml"> <input type=hidden id=article_uuid value=6b716b3e-6c5f-4a94-86d3-88fdeb968eb8 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Update on GH therapy in adults"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.12057.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.12057.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-2017"
  },
  "headline": "Update on GH therapy in adults",
  "datePublished": "2017-11-16T16:07:26",
  "dateModified": "2017-11-16T16:07:26",
  "author": [
    {
      "@type": "Person",
      "name": "Cesar Luiz Boguszewski"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Over the last three decades, short- and long-term observational studies, clinical trials, systematic reviews, and meta-analyses have provided relevant information on the efficacy and safety of growth hormone (GH) replacement therapy in adults with GH deficiency (AGHD). The knowledge acquired during this time has been compiled into different guidelines that offer clinicians an evidence-based, practical approach for the management of AGHD. There are, however, still open questions in some key areas in which recommendations are supported by only moderate or weak evidence. In the last recent years, the development of long-acting GH preparations has created new therapeutic possibilities by decreasing injection frequency, improving adherence and thereby potentially maximizing clinical outcomes. The aims of this review are to advance our understanding on the diagnosis and treatment of AGHD and to present an update and future perspectives on the use of long-acting GH preparations."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-2017",
            "name": "Update on GH therapy in adults"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Update on GH therapy in adults </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=13044 data-id=12057 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12057.1" data-recommended="" data-doi="10.12688/f1000research.12057.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-2017/v1/pdf?article_uuid=6b716b3e-6c5f-4a94-86d3-88fdeb968eb8" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-12057-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-12057-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-12057-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Boguszewski CL. Update on GH therapy in adults [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2017 (<a class=new-orange href="https://doi.org/10.12688/f1000research.12057.1" target=_blank>https://doi.org/10.12688/f1000research.12057.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-12057-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=12057 id=track-article-signin-12057 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12057?target=/articles/6-2017">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13044 /> <input name=articleId type=hidden value=12057 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Update on GH therapy in adults</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:clbogus@uol.com.br" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Cesar Luiz Boguszewski</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:clbogus@uol.com.br" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Cesar Luiz Boguszewski</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 16 Nov 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.12057.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Endocrine Division (SEMPR), Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil<br/> <p> <div class=margin-bottom> Cesar Luiz Boguszewski <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=27857-27769></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=27859-27770></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=27858-27768></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Over the last three decades, short- and long-term observational studies, clinical trials, systematic reviews, and meta-analyses have provided relevant information on the efficacy and safety of growth hormone (GH) replacement therapy in adults with GH deficiency (AGHD). The knowledge acquired during this time has been compiled into different guidelines that offer clinicians an evidence-based, practical approach for the management of AGHD. There are, however, still open questions in some key areas in which recommendations are supported by only moderate or weak evidence. In the last recent years, the development of long-acting GH preparations has created new therapeutic possibilities by decreasing injection frequency, improving adherence and thereby potentially maximizing clinical outcomes. The aims of this review are to advance our understanding on the diagnosis and treatment of AGHD and to present an update and future perspectives on the use of long-acting GH preparations. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> growth hormone,adults with GH deficiency,IGF-I </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Cesar Luiz Boguszewski (<a href="mailto:clbogus@uol.com.br">clbogus@uol.com.br</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Cesar Luiz Boguszewski </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Cesar Boguszewski has been a consultant for Pfizer. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Boguszewski CL. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Boguszewski CL. Update on GH therapy in adults [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2017 (<a href="https://doi.org/10.12688/f1000research.12057.1" target=_blank>https://doi.org/10.12688/f1000research.12057.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 16 Nov 2017, <b>6</b>(F1000 Faculty Rev):2017 (<a href="https://doi.org/10.12688/f1000research.12057.1" target=_blank>https://doi.org/10.12688/f1000research.12057.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 16 Nov 2017, <b>6</b>(F1000 Faculty Rev):2017 (<a href="https://doi.org/10.12688/f1000research.12057.1" target=_blank>https://doi.org/10.12688/f1000research.12057.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d60749e138>Introduction</h2><p class="" id=d60749e141>In 1962, a 35-year-old woman with hypopituitarism was the first adult treated with pituitary growth hormone (GH). She felt improvement in physical vigor and psychological well-being after two months of treatment<sup><a href="#ref-1">1</a></sup>. At that time, however, limited availability of pituitary GH restricted its therapeutic use to those few children with more severe forms of growth retardation. This problem was solved in 1985 with the introduction in the clinical practice of unrestricted amounts of recombinant human GH, which also created several novel therapeutic opportunities.</p><p class="" id=d60749e148>It was in this context that a new entity in hypopituitary patients receiving replacement therapy for thyroid-stimulating hormone (TSH), follicle-stimulating hormone/luteinizing hormone (FSH/LH) and/or adrenocorticotropic hormone (ACTH) deficiencies, but not for GH deficiency (GHD), started to be defined as: “adult GH deficiency” (AGHD)<sup><a href="#ref-2">2</a></sup>. The initial characterization of AGHD occurred in parallel with a Swedish epidemiologic study that demonstrated an increased mortality in patients with hypopituitarism, mainly related to cardiovascular complications<sup><a href="#ref-3">3</a></sup>. This pioneer study was followed by others confirming this finding, and a recent meta-analysis concluded that the risk of premature mortality in hypopituitarism is particularly high in women and in patients diagnosed at a younger age<sup><a href="#ref-4">4</a>–<a href="#ref-7">7</a></sup>. However, it is not defined to what extent untreated AGHD is responsible for the reduced life expectancy observed in hypopituitary patients, as many other factors—such as previous exposure to radiation, the etiology of the underlying hypothalamic-pituitary disease, or mistreatment of other associated pituitary hormone deficiencies—might also contribute to increased mortality<sup><a href="#ref-6">6</a>–<a href="#ref-9">9</a></sup>. Evidence from a Brazilian kindred with lifetime isolated GHD due to a homozygous mutation in the GH-releasing hormone (GHRH) receptor gene does not support a deleterious effect of congenital isolated GHD on survival<sup><a href="#ref-8">8</a></sup>. In this kindred, affected individuals exhibit normal longevity despite their dwarfism, visceral obesity, and the presence of some cardiovascular risk factors. Remarkably, these patients maintain increased insulin sensitivity and do not show premature atherosclerosis<sup><a href="#ref-8">8</a></sup>. In clear contrast, hypopituitary patients with more classic forms of AGHD usually have combined pituitary deficiencies, are insulin-resistant, and present several risk factors for vascular complications<sup><a href="#ref-2">2</a></sup>. These observations clearly demonstrate the heterogeneous nature of AGHD and highlight that the findings in one specific group may not necessarily be applicable to other groups of patients with AGHD.</p><p class="" id=d60749e186>Whether GH therapy is able to normalize or decrease mortality rates in hypopituitary patients is still an unsolved question. A nationwide registry study from Denmark found that in GH-treated patients, total mortality, and mortality due to malignancy were decreased compared with untreated patients even after adjustment for all possible measured confounders<sup><a href="#ref-9">9</a></sup>. Data from the Dutch National Registry of GH treatment in adults found gender differences in the effects of GH treatment on mortality. AGHD men receiving GH treatment had a mortality rate not different from that of the background population, while the standardized mortality ratio (SMR) due to cardiovascular disease was still increased in women even after exclusion of high-risk patients<sup><a href="#ref-10">10</a></sup>. A study from the KIMS database (Pfizer International Metabolic Database) involving 13, 983 GH-replaced hypopituitary patients found a modest increase in all-cause mortality (SMR 1.13, 95% confidence interval 1.04–1.24), lower than values previously published in untreated AGHD<sup><a href="#ref-11">11</a></sup>. Factors associated with increased mortality in the KIMS database were female gender, younger attained age, aggressive pituitary tumors, and lower insulin-like growth factor 1 (IGF-I) standard deviation score during therapy. Of note, cardiovascular disease and malignancy were the leading causes of death, but the overall SMR for these cause categories was not significantly increased<sup><a href="#ref-11">11</a></sup>. Accordingly, in another epidemiological study from the Swedish KIMS database, in which 99.7% of hypopituitary patients were receiving GH treatment, excess mortality was associated not with vascular diseases but with two preventable causes of death: adrenal crisis in response to acute stress and intercurrent illness, and increased risk of a late appearance of <i>de novo</i> malignant brain tumors in patients who previously received radiotherapy. The observed shift in the causes of death were claimed to be related not only with GH therapy but with improvements in surgical procedures and hormone replacement regimens over the last 10 to 15 years, less use of radiotherapy, and more efficient therapies to manage cardiovascular risk factors<sup><a href="#ref-12">12</a></sup>.</p><p class="" id=d60749e213>AGHD should not be confused with states of functional GHD, such as obesity and aging. Aging is associated with a physiological decline in GH and IGF-I secretion, sometimes referred to as “somatopause”<sup><a href="#ref-13">13</a>–<a href="#ref-19">19</a></sup>. It is important to emphasize that neither the safety nor the benefits of GH administration to re-establishing “youthful” GH levels in pituitary-replete adults have been demonstrated to justify the use of GH as an anti-aging agent, and in most countries it is illegal to prescribe GH for off-label indications<sup><a href="#ref-17">17</a>–<a href="#ref-20">20</a></sup>. Having these concepts in mind, this review will focus on who the adult candidates for GH therapy are, the criteria for a biochemical diagnosis of severe AGHD, and the optimal therapeutic approach and the impact of GH therapy in AGHD, including efficacy and safety issues. In the last part, a brief overview of the long-term GH preparations will be presented.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d60749e233>Adult candidates for growth hormone therapy</h2><p class="" id=d60749e236>AGHD should be investigated in all patients with evidence of a disease or trauma affecting the hypothalamic-pituitary region and in whom there is an intention to start treatment with GH<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. This concept is pivotal, as adults with no well-established hypothalamic-pituitary disease, in whom GH and IGF-I levels might be functionally reduced because of aging or excess of visceral adipose tissue, are not candidates for GH therapy and therefore must not be subjected to diagnostic procedures<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. The same concept is valid for short children treated with GH during childhood for non-GHD pediatric indications, such as Turner syndrome, small for gestational age, and idiopathic short stature (<a href="#f1">Figure 1</a>).</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/13044/7300f030-3962-47b8-be39-14b8defd96fb_figure1.gif"><img alt="7300f030-3962-47b8-be39-14b8defd96fb_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/13044/7300f030-3962-47b8-be39-14b8defd96fb_figure1.gif"></a><div class=caption><h3>Figure 1. Diagnostic approach of adult growth hormone deficiency (AGHD).</h3><p id=d60749e266>Asterisk indicates that “– 2 SD (standard deviation)” corresponds to IGF-I levels below the lower limit of the reference values adjusted for age. Hash sign indicates that, if available, growth hormone–releasing hormone plus arginine (GHRH+ARG) test is the best alternative for ITT, and corresponding diagnostic peak values are shown in the dashed rectangle. BMI, body mass index; GH, growth hormone; GHD, growth hormone deficiency; GST, glucagon stimulation test; IGF-I, insulin-like growth factor 1; ITT, insulin tolerance test.</p></div></div><p class="" id=d60749e273>The causes of AGHD are multiple and include genetic defects; congenital malformations; trauma; sub-arachnoid hemorrhage; non-functioning and functioning pituitary adenomas (for example, prolactinoma, Cushing’s disease, and iatrogenic consequence of the acromegaly treatment); craniopharyngiomas; infiltrative, inflammatory, and vascular diseases; neurosurgery; and radiotherapy<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. Traditionally, pituitary adenomas or their treatment (or both) have been listed as the most frequent causes of AGHD, but more recent studies have demonstrated an increasing prevalence of non-tumoral disorders, including traumatic brain injury and head trauma related to sports (boxing, kickboxing, soccer, football, ice hockey, and rugby)<sup><a href="#ref-21">21</a></sup>. Additionally, some studies have highlighted the importance of Sheehan’s syndrome as one of the leading causes of hypopituitarism and AGHD in adult women living in underdeveloped and developing countries<sup><a href="#ref-21">21</a></sup>. Manifestations of AGHD, owing to its heterogeneous nature, are variable, depending on how and when the disease is installed. Thus, AGHD can be diagnosed in association with other pituitary hormone deficiencies (combined AGHD) or alone (isolated AGHD). The disease can begin <i>de novo</i> in adult life (adulthood-onset) or can be diagnosed by GH tests in childhood persisting into adult life (childhood-onset)<sup><a href="#ref-22">22</a></sup>. In our hands, 56% of patients with idiopathic isolated GHD during childhood had no biochemical criteria for AGHD when re-tested in adult life, whereas 94% of those with combined GHD during childhood persisted with AGHD<sup><a href="#ref-23">23</a></sup>. Finally, another pivotal concept is related to the severity of the disease. Only patients with severe AGHD (as defined by strict biochemical criteria) are appropriate candidates for GH replacement therapy, as partial AGHD (or GH insufficiency) is still a poorly defined entity in which GH therapy is not indicated<sup><a href="#ref-24">24</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d60749e310>Biochemical diagnosis of adult growth hormone deficiency</h2><p class="" id=d60749e313>The clinical findings of AGHD are non-specific and usually of little diagnostic value (<a href="#T1">Table 1</a>). Thus, the presence of AGHD can be confirmed only by using an appropriate biochemical approach with GH and IGF-I measurements. The insulin tolerance test (ITT) and the GHRH plus arginine (GHRH+ARG) stimulation test have been traditionally used as the choice diagnostic procedures for AGHD<sup><a href="#ref-2">2</a>,<a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. However, the GHRH analogue is not widely available, making the GHRH+ARG test impractical in many countries around the world<sup><a href="#ref-25">25</a></sup>. As a consequence, the glucagon stimulation test (GST) has emerged as the best alternative for cases in which ITT is unsuitable or contraindicated<sup><a href="#ref-25">25</a>–<a href="#ref-29">29</a></sup>. Some provocative tests frequently used to investigate GHD in children, which include arginine, clonidine, and L-dopa, are not valid for diagnosing AGHD<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. Each GH stimulation test has advantages and limitations, and the choice must take in account contraindications, risks, and availability. It is also important to consider the high variability of GH results produced by different GH assays and to be aware of the assay and laboratory used for GH measurements<sup><a href="#ref-30">30</a></sup>. In most cases, an impaired peak GH level in one test is sufficient to diagnose AGHD<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Clinical abnormalities in hypopituitary adult patients with growth hormone deficiency (AGHD).</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d60749e370 class=n-a></a><thead><a name=d60749e372 class=n-a></a><tr><a name=d60749e374 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d60749e376 class=n-a></a>Clinical abnormalities</th><th align=left colspan=1 rowspan=1><a name=d60749e379 class=n-a></a>Effect of growth hormone deficiency</th></tr></thead><tbody><a name=d60749e384 class=n-a></a><tr><a name=d60749e386 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e388 class=n-a></a>Changes in body composition</td><td colspan=1 rowspan=1 valign=top><a name=d60749e391 class=n-a></a>Increased total and visceral adiposity<br class=br>Reduced body lean mass<br class=br>Reduced bone mineral density (especially<br class=br>in transition and young adults)</td></tr><tr><a name=d60749e401 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e403 class=n-a></a>Impairment of cognitive and psycho-social<br class=br>functions (poor quality of life)</td><td colspan=1 rowspan=1 valign=top><a name=d60749e408 class=n-a></a>Fatigue (low energy, reduced vitality)<br class=br>Low self-esteem<br class=br>Bad mood<br class=br>Reduced concentration<br class=br>Reduced memory<br class=br>Increased sick days<br class=br>Greater social isolation</td></tr><tr><a name=d60749e425 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e427 class=n-a></a>Altered physical capacity</td><td colspan=1 rowspan=1 valign=top><a name=d60749e430 class=n-a></a>Reduced muscular strength<br class=br>Reduced maximum oxygen uptake<br class=br>Impaired cardiac function<br class=br>Hypohydrosis</td></tr><tr><a name=d60749e440 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e442 class=n-a></a>Presence of cardiovascular risk factors</td><td colspan=1 rowspan=1 valign=top><a name=d60749e445 class=n-a></a>Dyslipidemia<br class=br>Insulin resistance (visceral obesity)<br class=br>Abnormal fibrinolytic activity<br class=br>Increased pro-inflammatory markers<br class=br>Increased intimal media thickening</td></tr></tbody></table></div><p class="" id=d60749e460>Peak GH values in GH tests are influenced by several factors, including age, adiposity, and the type of GH secretagogue<sup><a href="#ref-31">31</a>–<a href="#ref-33">33</a></sup>. In the ITT, the validated cutoff value for biochemical diagnosis of severe AGHD is a peak GH response lower than 3 µg/L<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. Nevertheless, the threshold value differs in patients in the transition phase—a period of time arbitrarily defined as “a 6–7 years interval spanning from late puberty (after achievement of final height) to the full adult somatic maturation”<sup><a href="#ref-12">12</a>,<a href="#ref-29">29</a></sup>. In the transition, a higher cutoff of 5 µg/L<sup><a href="#ref-34">34</a></sup> or 6.1 µg/L<sup><a href="#ref-35">35</a></sup> in the ITT has been recommended for the biochemical diagnosis. The cutoff value of 3 µg/L has also been recommended to discriminate between normal response and severe AGHD in the GST<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-26">26</a></sup>, but a lower threshold of 1 µg/L was recently proposed for overweight/obese subjects, as obesity blunts GH response to glucagon stimulation<sup><a href="#ref-28">28</a>,<a href="#ref-36">36</a></sup>. Similarly, cut-point levels in the GHRH+ARG test should be interpreted according to body mass index (BMI): 11.5 µg/L for patients with a BMI of less than 25 kg/m<sup>2</sup>, 8 µg/L for a BMI of 25–30 kg/m<sup>2</sup>, and 4.2 µg/L for those with a BMI of greater than 30 kg/m<sup>2</sup><sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d60749e522>GH stimulation tests are not always necessary for the final diagnosis of AGHD. As shown in <a href="#f1">Figure 1</a>, the investigation can be oriented by the pre-test probability for AGHD. When there is a high probability of AGHD, single IGF-I measurements might be sufficient to make the diagnosis. For instance, in hypopituitary patients with three or more pituitary deficiencies, especially those who are younger than 40 years and have a BMI of below 25 kg/m<sup>2</sup>, a low serum IGF-I level (below the lower limit of the reference range for age), in the absence of catabolic conditions or liver diseases, is highly indicative of severe AGHD<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. In contrast, a normal serum IGF-I level in a hypopituitary patient does not exclude AGHD at any age, and the investigation should continue with a GH test. One important point to be highlighted is that the interpretation of IGF-I measurements can be challenged, as the results are highly variable among different assays and influenced by several factors, such as assay characteristics, gender, age, and reference values<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-30">30</a></sup>. In cases in which the pre-test probability of AGHD is low, as in transition patients diagnosed with idiopathic isolated GHD by stimulation tests during childhood or in obese and elderly hypopituitary patients, both GH test and IGF-I measurements are needed for establishing the diagnosis<sup><a href="#ref-15">15</a>,<a href="#ref-34">34</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d60749e558>Impact of growth hormone therapy in adult growth hormone deficiency</h2><p class="" id=d60749e561>GH replacement therapy might normalize abnormalities related to the AGHD state and promote numerous health benefits for hypopituitary patients<sup><a href="#ref-2">2</a>,<a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-19">19</a>,<a href="#ref-20">20</a>,<a href="#ref-37">37</a></sup>. In young adults with persistent GHD in the transition period, continuation or reintroduction of replacement treatment with GH after attaining final height promotes full somatic development of bone and muscles and prevents the development of AGHD features observed in older patients<sup><a href="#ref-15">15</a>,<a href="#ref-34">34</a>,<a href="#ref-35">35</a>,<a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. GH treatment in AGHD reduces total and visceral fat mass, increases lean body mass and bone mass, and improves exercise capacity and quality of life (QoL)<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. A meta-analysis of placebo-controlled trials showed an improvement in cardiovascular risk markers, including diastolic blood pressure, total cholesterol, and low-density lipoprotein cholesterol<sup><a href="#ref-40">40</a></sup>. Another meta-analysis found strong evidence that GH replacement improves exercise performance in AGHD<sup><a href="#ref-41">41</a></sup>. Recently, two meta-analyses have suggested a beneficial effect of GH therapy on bone mineral density in AGHD, which was mainly affected by gender, age, GH dose, and treatment duration<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>. In relation to QoL, one meta-analysis showed a significant difference in favor of GH therapy only on the Nottingham Health Profile social isolation dimension<sup><a href="#ref-44">44</a></sup>, but in cohorts of AGHD followed up to 10 years, a sustained improvement in QoL scores toward normality has been demonstrated, and there were more marked effects in women and in patients with low QoL at baseline<sup><a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>. It is worth mentioning that analysis of pros and cons of GH therapy might suffer interference from the associated pituitary deficiencies and from the adequacy of other replacement therapies. For instance, the avoidance of over- or under-replacement with glucocorticoids, sex steroids, and levothyroxine is fundamental to improve morbidities that are frequently associated with hypopituitarism<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>.</p><p class="" id=d60749e640>The clinical response to GH therapy is highly variable among patients with AGHD and is influenced by gender, age, BMI, GH dose, and the route of estrogen replacement in hypopituitary women<sup><a href="#ref-2">2</a>,<a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. In a collaborative study between my institution and the Sahlgrenska Academy, University of Gothenburg, Sweden, we have developed mathematical models based on clinical parameters aimed at identifying good and poor responders to GH therapy<sup><a href="#ref-51">51</a></sup>. Using 1-year changes in serum IGF-I and body composition as therapeutic outcomes, we found that gender, body height, lean body mass, and serum insulin levels were the main clinical predictors of GH response in our models. In addition, we have investigated genetic factors that could be implicated with the variable response to GH therapy at different endpoints<sup><a href="#ref-52">52</a>–<a href="#ref-54">54</a></sup>. Using a candidate gene approach, we could identify associations between individual polymorphisms in genes related to lipid metabolism with serum lipid profile and in genes related to renal tubular function with extracellular water volume and blood pressure in AGHD patients both at baseline and after 1 year of GH therapy<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. In two other studies, we examined the impact of the exon 3-deleted GH receptor (d3-GHR) isoform on the short-term (1 week) and long-term (1 year) responses to GH therapy in AGHD<sup><a href="#ref-51">51</a>,<a href="#ref-55">55</a></sup>. We found that carriers of the d3-GHR isoform had a poorer IGF-I response to GH after 1 week of therapy than full-length GHR homozygote individuals but that such an association was not observed after 1 year. This discrepant result might be explained by the fact that long-term studies are more subject to confounders such as dose titration and adherence to the treatment than the short-term model. The GHR polymorphism has been studied in other cohorts of patients with AGHD and the results, as expected, have been conflicting<sup><a href="#ref-56">56</a>–<a href="#ref-62">62</a></sup>. Thus, it is not clear at this moment whether the GHR polymorphism exerts some influence on GH responsiveness in adults, but if it does, the magnitude of the effect is likely to be modest. Further prospective, multicenter, pharmacogenetics studies in larger populations of patients with AGHD might help to define the relevance of clinical and genetic factors for GH responses, allowing the development of good prediction models to optimize therapeutic outcomes.</p><p class="" id=d60749e692>GH replacement is, in general, a safe and well-tolerated therapy in hypopituitary patients. However, special attention should be given to older, heavier, and female patients with AGHD because they are more susceptible to adverse events<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. Individuals with AGHD are insulin-resistant because of increased adiposity, reduced lean body mass, and impaired physical performance. Insulin resistance might temporarily worsen in the first months of treatment because of diabetogenic effects of GH<sup><a href="#ref-63">63</a></sup>. The latter is usually compensated in the long-term therapy by the lipolytic actions of GH. Nevertheless, close monitoring of glucose status is advisable during GH treatment in a subset of AGHD patients with obesity or a family history of type 2 diabetes or both, because they are more prone to exhibit impaired glucose tolerance and diabetes mellitus in the first year of therapy<sup><a href="#ref-20">20</a></sup>. Owing to GH effects on thyroid hormones and cortisol metabolism, a pre-existing subclinical central hypothyroidism and secondary adrenal insufficiency might be unmasked during GH therapy. Therefore, patients should be carefully monitored for clinical manifestations of adrenal insufficiency or hypothyroidism, and free thyroxine and cortisol levels should be followed regularly during the initial phases of the treatment<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-20">20</a>,<a href="#ref-64">64</a></sup>.</p><p class="" id=d60749e723>Despite the potential role of GH and IGF-I in cell proliferation<sup><a href="#ref-65">65</a></sup>, there is no evidence of increased recurrence rates of intra-cranial or extra-cranial tumors among patients taking GH for AGHD<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-20">20</a>,<a href="#ref-66">66</a></sup>. However, GH should not be given to patients with active malignancy<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-20">20</a></sup>. There are few reports of long-term studies quantifying the increased risk, if any, of <i>de novo</i> malignancies. A recent Swedish study involving 426 patients with non-functioning pituitary adenomas—of whom 207 received GH therapy for a median period of 12.2 years and 219 were untreated patients with a median follow-up of 8.2 years—showed a reduced overall mortality in GH-treated patients compared with the general population and found that death due to malignancy was not increased in GH-treated patients<sup><a href="#ref-67">67</a></sup>. In addition, a recent meta-analysis including two retrospective and seven prospective studies with a total of 11,191 participants presented a reassuring conclusion that GH replacement therapy was associated with a reduced risk of cancer in AGHD<sup><a href="#ref-68">68</a></sup>. Nevertheless, it appears to be a slight excess risk of second neoplasia related to GH therapy among “high-risk” children, including patients with syndromes, diseases, and mutations known to be associated with an inherent elevated risk for cancer and early mortality, such as those with neurofibromatosis type 1, Fanconi anemia, and Down syndrome, but no comparable data are available for patients with AGHD<sup><a href="#ref-20">20</a></sup>. Hence, additional caution should be taken in AGHD patients with a history of cancer, strong family history of cancer, and advancing age<sup><a href="#ref-66">66</a>,<a href="#ref-69">69</a></sup>. Taken together, the evidence available at present demonstrates that the benefits of GH therapy in AGHD outweigh the theoretical cancer risk and that the screening for malignancies in GH-treated adults should follow the same rules applied for the general population<sup><a href="#ref-20">20</a>,<a href="#ref-66">66</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d60749e786>Therapeutic approach in adult growth hormone deficiency</h2><p class="" id=d60749e789>In contrast with GH treatment in children, the replacement doses of GH in AGHD are not calculated on the basis of body weight, because this approach results in a high frequency of adverse events, mainly related to fluid retention: paresthesias, joint stiffness, peripheral edema, arthralgia, myalgia, and carpal tunnel syndrome<sup><a href="#ref-2">2</a></sup>. Thus, GH therapy in adults is initiated with low doses, which are progressively up-titrated to attain normal IGF-I levels<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. At the start, the usual recommendation is a daily dose of 0.2 mg for young men, 0.3 mg for young women, and 0.1 mg for older individuals, which should be subcutaneously administered at bedtime (<a href="#f2">Figure 2</a>). In patients transitioning from pediatric treatment, initial doses typically have been intermediate between those used in the pediatric and in the adult population, which can be as high as 0.5–0.7 mg<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a>,<a href="#ref-70">70</a></sup>. The dose of GH is then increased gradually, at intervals of 1 to 2 months, in an individualized manner and guided by clinical assessments, side effects, and serum IGF-I levels. The objective is to attain and maintain normal IGF-I levels, preferably between the median and upper limit of the age-related normal range, always using the same IGF-I assay during the follow-up<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-30">30</a></sup>. There are scarce data specifically addressing how to monitor therapy in AGHD patients with normal IGF-I levels at baseline<sup><a href="#ref-70">70</a></sup>. As a general rule, however, the same dose titration approach should be applied with the aim of increasing IGF-I levels into the upper normal range and simultaneously monitoring efficacy through other therapeutic outcomes, such as body composition, cardiovascular risk factors, and QoL. Despite the importance of attaining normal IGF-I levels, in one of our previous studies we observed a significant impact of GH therapy on body composition with a fixed low-dose regimen maintained during 1 year, even in cases where IGF-I levels were not normalized<sup><a href="#ref-71">71</a></sup>. On the other hand, IGF-I levels above the upper limit of normal during GH therapy should always be interpreted as over-treatment, and dose adjustment is mandatory<sup><a href="#ref-2">2</a>,<a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>.</p><div class="fig panel clearfix"><a name=f2 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/13044/7300f030-3962-47b8-be39-14b8defd96fb_figure2.gif"><img alt="7300f030-3962-47b8-be39-14b8defd96fb_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/13044/7300f030-3962-47b8-be39-14b8defd96fb_figure2.gif"></a><div class=caption><h3>Figure 2. Therapeutic and follow-up procedures for growth hormone (GH) replacement therapy in adult growth hormone deficiency (AGHD).</h3><p id=d60749e855>BMD, bone mineral density; BMI, body mass index; BP, blood pressure; DXA, dual-energy x-ray absorptiometry; IGF-I, insulin-like growth factor 1; QoL, quality of life; SC, subcutaneous.</p></div></div><p class="" id=d60749e862>Once the maintenance dose of GH is achieved, IGF-I levels should be measured every 6 or 12 months to ensure that levels are kept in the normal range and below the upper limit to avoid over-treatment. As previously mentioned, the maintenance dose varies considerably from patient to patient, depending on factors such as age, gender, adiposity, and hormone interactions<sup><a href="#ref-37">37</a>–<a href="#ref-39">39</a>,<a href="#ref-48">48</a>–<a href="#ref-50">50</a>,<a href="#ref-64">64</a></sup>. For example, oral estrogen has been shown to have GH-antagonist effects; consequently, hypopituitary women in use of oral estrogen need much higher doses of GH to normalize IGF-I levels<sup><a href="#ref-50">50</a>,<a href="#ref-64">64</a></sup>. Therefore, as soon as GH treatment is prescribed, a non-oral route of exogenous estrogen should be prescribed for hypopituitary women<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-50">50</a>,<a href="#ref-64">64</a></sup>. Similarly, levothyroxine therapy might require adjustments, as weight-based doses of thyroid hormone are usually higher in AGHD patients under GH treatment<sup><a href="#ref-13">13</a>,<a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>. Conceptually, GH replacement should be a lifelong treatment, but its length has been a matter of debate. The physiological decline of GH secretion during the aging process is one reason for those who advocate stopping the treatment as patients get older. In contrast, there have been claims that there is no reason to stop treatment if clear benefits are being persistently achieved. Notably, regardless of the patient’s age, if no apparent or objective benefits of treatment have been observed after at least 1 year of follow-up, the discontinuation of GH therapy should be considered<sup><a href="#ref-13">13</a>,<a href="#ref-37">37</a></sup>.</p><p class="" id=d60749e918>Disease-generated questionnaires such as “Assessment of GHD in Adults” (QoL-AGHD) and general questionnaires such as “Psychological General Well-Being” and “Nottingham Health Profile” have been validated to measure a variety of health-related, economic, and social factors and are mainly used as research tools<sup><a href="#ref-74">74</a>,<a href="#ref-75">75</a></sup>. In some specialized centers, however, QoL-AGHD has been applied as a key tool for both starting and monitoring GH therapy in patients with AGHD. In most clinical settings, where these questionnaires are unavailable, health-related QoL outcomes, such as energy levels, partner satisfaction, sick days, and vitality, can be monitored by careful anamnesis before and after GH therapy, allowing a comprehensive view of potential therapeutic benefits in these parameters<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup>. In untreated AGHD, QoL evaluations have shown a high degree of variability, from normal to severe impairment, affecting mainly energy and vitality. As a rule, if the QoL is normal at baseline, no major improvement should be expected with GH therapy, while the degree of improvement is generally proportional to the deviation from normality<sup><a href="#ref-13">13</a>,<a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>.</p><p class="" id=d60749e946>During GH therapy, changes in body composition need to be documented. While simple anthropometry with determination of BMI, skin folds, and waist circumference are easy to record, more objective measurements are preferable. Ideally, patients should have pre-treatment dual-energy x-ray absorptiometry, which should be repeated every one or two years to assess fat mass and lean body mass changes and every two years to evaluate bone mineral density changes. It is recommended that cardiovascular risk factors (particularly blood pressure, lipid profile, and glucose) be evaluated every 6 or 12 months<sup><a href="#ref-13">13</a>–<a href="#ref-16">16</a>,<a href="#ref-37">37</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d60749e963>Future perspectives</h2><p class="" id=d60749e966>Daily subcutaneous injections of GH might be laborious and cumbersome for some patients, leading to poor adherence that increases over time and compromises therapeutic efficacy. In this context, long-acting GH (LAGH) preparations requiring one injection per week, every two weeks, or once a month may offer a possible alternative to daily subcutaneous injections. As summarized in <a href="#T2">Table 2</a>, there are LAGH preparations in various stages of development, including depot, pegylated, and prodrug formulations as well as non-covalent albumin-binding GH and GH-fusion proteins compounds<sup><a href="#ref-76">76</a></sup>. A review of efficacy and safety of LAGH preparations was recently published after an expert workshop held by the Growth Hormone Research Society<sup><a href="#ref-77">77</a></sup>. The expert panel concluded that each LAGH formulation has different pharmacokinetics and pharmacodynamics and therefore safety issues need to be addressed in an individualized and specific manner, with no comparison with those related to daily GH injections. Among the main safety concerns are the maintenance of supra-physiological elevations of GH or IGF-I levels (or both) and non-physiological tissue distribution<sup><a href="#ref-76">76</a>,<a href="#ref-77">77</a></sup>. As long-term data of LAGH preparations are unavailable, only prolonged monitoring will help to shed light on their safety profiles.</p><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Overview of the currently available long-acting growth hormone preparations.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d60749e998 class=n-a></a><thead><a name=d60749e1000 class=n-a></a><tr><a name=d60749e1002 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d60749e1004 class=n-a></a>Formulation</th><th align=left colspan=1 rowspan=1><a name=d60749e1007 class=n-a></a>Product</th><th align=left colspan=1 rowspan=1><a name=d60749e1010 class=n-a></a>Structure</th><th align=left colspan=1 rowspan=1><a name=d60749e1013 class=n-a></a>Frequency of<br class=br>administration</th><th align=left colspan=1 rowspan=1><a name=d60749e1018 class=n-a></a>Current status</th></tr></thead><tbody><a name=d60749e1023 class=n-a></a><tr><a name=d60749e1025 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1027 class=n-a></a>Depot</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1030 class=n-a></a>LB03002</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1033 class=n-a></a>Microparticles containing GH<br class=br>incorporated into sodium hyaluronate<br class=br>and dispersed in an oil base of<br class=br>medium-chain triglycerides</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1042 class=n-a></a>Every week</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1045 class=n-a></a>Approved in Europe<br class=br>Approved in Korea for<br class=br>children with GHD</td></tr><tr><a name=d60749e1053 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1055 class=n-a></a>Pegylated</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1058 class=n-a></a>CP016</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1061 class=n-a></a>Nasal spray formulation</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1064 class=n-a></a>Every 2 weeks (planned)</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1067 class=n-a></a>Preclinical studies</td></tr><tr><a name=d60749e1071 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1073 class=n-a></a>Pegylated</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1076 class=n-a></a>BBT-031</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1079 class=n-a></a>Site-specific pegylated GH analog</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1082 class=n-a></a>Every week (planned)</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1085 class=n-a></a>Preclinical studies</td></tr><tr><a name=d60749e1089 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1091 class=n-a></a>Pegylated</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1094 class=n-a></a>Jintrolong</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1097 class=n-a></a>40-kDa polyethylene glycol attached<br class=br>to GH</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1102 class=n-a></a>Every week</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1105 class=n-a></a>Approved in China only<br class=br>for children with GHD</td></tr><tr><a name=d60749e1111 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1113 class=n-a></a>Prodrug</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1116 class=n-a></a>TransCon (ACP-001)</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1119 class=n-a></a>Unmodified GH transiently linked to a<br class=br>carrier molecule</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1124 class=n-a></a>Every week</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1127 class=n-a></a>Phase 2 studies in<br class=br>children and adults</td></tr><tr><a name=d60749e1134 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1136 class=n-a></a>Prodrug</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1139 class=n-a></a>NNC0195-0092</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1142 class=n-a></a>Single-point mutation in GH molecule<br class=br>with albumin binding moiety attached</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1147 class=n-a></a>Every week</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1150 class=n-a></a>Phase 2 studies in<br class=br>children and phase 3 in<br class=br>adults</td></tr><tr><a name=d60749e1158 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1160 class=n-a></a>GH fusion protein</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1163 class=n-a></a>ProFuse GH</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1166 class=n-a></a>GH-binding protein</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1169 class=n-a></a>Every month (planned)</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1172 class=n-a></a>Preclinical studies</td></tr><tr><a name=d60749e1176 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1178 class=n-a></a>GH fusion protein</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1181 class=n-a></a>GX-H9</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1184 class=n-a></a>Hybridization of non-cytolytic<br class=br>immunoglobulin Fc portion of IgD and<br class=br>IgG4</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1191 class=n-a></a>Every week or two<br class=br>weeks</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1196 class=n-a></a>Phase 2 studies in adults</td></tr><tr><a name=d60749e1200 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1202 class=n-a></a>GH fusion protein</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1205 class=n-a></a>LAPSrhGH/HM10560A</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1208 class=n-a></a>Homodimeric aglycosylated IgG4<br class=br>Fc fragment</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1213 class=n-a></a>Every week or two<br class=br>weeks</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1218 class=n-a></a>Phase 2 studies in adults</td></tr><tr><a name=d60749e1222 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1224 class=n-a></a>GH fusion protein</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1227 class=n-a></a>MOD-4023</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1230 class=n-a></a>Carboxyl-terminal peptide of hCG beta-<br class=br>subunit</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1235 class=n-a></a>Every week</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1238 class=n-a></a>Phase 2 studies in<br class=br>children and phase 3 in<br class=br>adults</td></tr><tr><a name=d60749e1246 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d60749e1248 class=n-a></a>GH fusion protein</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1251 class=n-a></a>VRS-317</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1254 class=n-a></a>rhGH plus long chains of natural<br class=br>hydrophilic amino acids (XTEN<br class=br>sequence)</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1261 class=n-a></a>Every week or two<br class=br>weeks</td><td colspan=1 rowspan=1 valign=top><a name=d60749e1266 class=n-a></a>Phase 3 studies in<br class=br>children and phase 2 in<br class=br>adults</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d60749e1278 class=n-a></a><p id=d60749e1280> GH, growth hormone; GHD, growth hormone deficiency.</p></div></div></div><p class="" id=d60749e1286>The LAGH used in clinical trials thus far did not result in tachyphylaxis and showed similar clinical effects in comparison with daily GH injections<sup><a href="#ref-76">76</a>,<a href="#ref-77">77</a></sup>. Hoffman <i>et al</i>.<sup><a href="#ref-78">78</a></sup> carried out a multicenter, open-label, randomized trial including 135 patients with AGHD: 51 received a depot GH preparation every two weeks, 53 received daily GH injections, and 31 were not treated. After 32 weeks, GH-treated groups showed a significant reduction of trunk and visceral adipose tissue and an increase in lean body mass in comparison with the untreated group. The depot formulation was as effective as daily GH injections. Similarly, in a placebo-controlled trial, Biller <i>et al</i>.<sup><a href="#ref-79">79</a></sup> observed a significant reduction of fat mass (mainly due to decreased trunk fat) and increase in lean body mass in AGHD patients after 6 months of treatment with a sustained-release GH formulation. This trial continued in an open-label extension phase up to 52 weeks, which confirmed a prolonged and sustained effect of the LAGH preparation in reducing fat mass and increasing lean body mass, serum IGF-I, and IGF-binding protein 3 (IGFBP-3) level<sup><a href="#ref-80">80</a></sup>. While these preliminary data reassure the non-inferiority of LAGH preparations in relation to daily GH injections, their efficacy and safety over years and their implication for costs and compliance remain to be elucidated in ongoing and future clinical trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d60749e1318>Closing remarks</h2><p class="" id=d60749e1321>This review has tried to offer a pragmatic approach to the management of AGHD. Currently, adult patients with evidence of any abnormality of the hypothalamic-pituitary area should be considered for evaluation of severe GHD and replacement therapy with GH. AGHD is a heterogeneous condition characterized by multiple, non-specific, clinical abnormalities whose diagnosis is based on GH tests and single IGF-I measurements. The ITT and GHRH+ARG are preferable biochemical tools, and the GST is the best alternative for cases in which these tests are unavailable or contraindicated. In cases in which the probability of AGHD is very high, a low IGF-I level is sufficient for diagnosis, without the need for additional provocative testing. In cases in which the probability is low, a normal IGF-I level does not exclude the diagnosis and performing a GH test is imperative. The question of whether GH therapy reduces mortality in hypopituitarism has no definite answer yet. What is well recognized is that GH therapy can correct or improve clinical abnormalities seen in patients with AGHD, resulting in beneficial effects on body composition, skeletal integrity, exercise capacity, QoL, and cardiovascular risk factors. Protocols for GH dosing regimens and guidelines for monitoring efficacy and safety are well established and easily available. Observational studies with at least 7 years of follow-up have demonstrated that many clinical benefits of GH therapy in patients with AGHD are sustained in the long term with a low prevalence of serious adverse events and complications<sup><a href="#ref-46">46</a>,<a href="#ref-81">81</a>–<a href="#ref-86">86</a></sup>. More research is needed in some key areas, such as better characterization of partial AGHD, optimization of care during transition, development of mathematical models to predict individual responses to GH therapy, impact of GH therapy in the mortality rates of hypopituitary patients, and therapeutic potential of the LAGH preparations.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d60749e1 class=n-a></a><h2 class=main-title id=d61003>Competing interests</h2><p class=metadata-entry><a name=d60749e75 class=n-a></a><p id=d60749e76> Cesar Boguszewski has been a consultant for Pfizer.</p></p></div><div class=back-section><a name=d60749e1 class=n-a></a><h2 class=main-title id=d61005>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d60749e1338 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d61278>References</h2><div class="section ref-list"><a name=d60749e1338 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d60749e1345 class=n-a></a>Raben MS: Growth hormone. 2. Clinical use of human growth hormone. <i>N Engl J Med.</i> 1962; <b>266</b>: 82–6 concl. <a target=xrefwindow id=d60749e1353 href="http://www.ncbi.nlm.nih.gov/pubmed/14489585">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1356 href="http://dx.doi.org/10.1056/NEJM196201112660207">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d60749e1365 class=n-a></a>Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. <i>J Clin Endocrinol Metab.</i> 1998; <b>83</b>(2): 379–81. <a target=xrefwindow id=d60749e1373 href="http://www.ncbi.nlm.nih.gov/pubmed/9467545">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1376 href="http://dx.doi.org/10.1210/jcem.83.2.4611">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d60749e1385 class=n-a></a>Rosén T, Bengtsson BA: Premature mortality due to cardiovascular disease in hypopituitarism. <i>Lancet.</i> 1990; <b>336</b>(8710): 285–8. <a target=xrefwindow id=d60749e1393 href="http://www.ncbi.nlm.nih.gov/pubmed/1973979">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1396 href="http://dx.doi.org/10.1016/0140-6736(90)91812-O">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d60749e1405 class=n-a></a>Bülow B, Hagmar L, Eskilsson J, <i> et al.</i>: Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. <i>J Clin Endocrinol Metab.</i> 2000; <b>85</b>(2): 574–84. <a target=xrefwindow id=d60749e1416 href="http://www.ncbi.nlm.nih.gov/pubmed/10690858">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1419 href="http://dx.doi.org/10.1210/jcem.85.2.6346">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d60749e1428 class=n-a></a>Tomlinson JW, Holden N, Hills RK, <i> et al.</i>: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. <i>Lancet.</i> 2001; <b>357</b>(9254): 425–31. <a target=xrefwindow id=d60749e1439 href="http://www.ncbi.nlm.nih.gov/pubmed/11273062">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1442 href="http://dx.doi.org/10.1016/S0140-6736(00)04006-X">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725347334"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e1452 class=n-a></a>Pappachan JM, Raskauskiene D, Kutty VR, <i> et al.</i>: Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(4): 1405–11. <a target=xrefwindow id=d60749e1463 href="http://www.ncbi.nlm.nih.gov/pubmed/25658016">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1466 href="http://dx.doi.org/10.1210/jc.2014-3787">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725347334">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726930903"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e1479 class=n-a></a>Jasim S, Alahdab F, Ahmed AT, <i> et al.</i>: Mortality in adults with hypopituitarism: a systematic review and meta-analysis. <i>Endocrine.</i> 2017; <b>56</b>(1): 33–42. <a target=xrefwindow id=d60749e1490 href="http://www.ncbi.nlm.nih.gov/pubmed/27817141">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1493 href="http://dx.doi.org/10.1007/s12020-016-1159-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726930903">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d60749e1506 class=n-a></a>Aguiar-Oliveira MH, Souza AHO, Oliveira CRP, <i> et al.</i>: MECHANISMS IN ENDOCRINOLOGY: The multiple facets of GHRH/GH/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation. <i>Eur J Endockrinol.</i> 2017; <b>177</b>(2): R85–R97. <a target=xrefwindow id=d60749e1517 href="http://www.ncbi.nlm.nih.gov/pubmed/28428227">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1520 href="http://dx.doi.org/10.1530/EJE-16-1047">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718544484"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e1529 class=n-a></a>Stochholm K, Berglund A, Juul S, <i> et al.</i>: Socioeconomic factors do not but GH treatment does affect mortality in adult-onset growth hormone deficiency. <i>J Clin Endocrinol Metab.</i> 2014; <b>99</b>(11): 4141–8. <a target=xrefwindow id=d60749e1540 href="http://www.ncbi.nlm.nih.gov/pubmed/25157542">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1543 href="http://dx.doi.org/10.1210/jc.2014-1814">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718544484">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13361038"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e1556 class=n-a></a>van Bunderen CC, van Nieuwpoort IC, Arwert LI, <i> et al.</i>: Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. <i>J Clin Endocrinol Metab.</i> 2011; <b>96</b>(10): 3151–9. <a target=xrefwindow id=d60749e1567 href="http://www.ncbi.nlm.nih.gov/pubmed/21849531">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1570 href="http://dx.doi.org/10.1210/jc.2011-1215">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13361038">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d60749e1583 class=n-a></a>Gaillard RC, Mattsson AF, Akerblad A, <i> et al.</i>: Overall and cause-specific mortality in GH-deficient adults on GH replacement. <i>Eur J Endocrinol.</i> 2012; <b>166</b>(6): 1069–77. <a target=xrefwindow id=d60749e1594 href="http://www.ncbi.nlm.nih.gov/pubmed/22457236">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1597 href="http://dx.doi.org/10.1530/EJE-11-1028">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d60749e1607 class=n-a></a>Burman P, Mattsson AF, Johannsson G, <i> et al.</i>: Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and <i>de novo</i> malignant brain tumors contribute to an increased mortality. <i>J Clin Endocrinol Metab.</i> 2013; <b>98</b>(4): 1466–75. <a target=xrefwindow id=d60749e1621 href="http://www.ncbi.nlm.nih.gov/pubmed/23457412">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1625 href="http://dx.doi.org/10.1210/jc.2012-4059">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d60749e1634 class=n-a></a>Molitch ME, Clemmons DR, Malozowski S, <i> et al.</i>: Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab.</i> 2011; <b>96</b>(6): 1587–609. <a target=xrefwindow id=d60749e1645 href="http://www.ncbi.nlm.nih.gov/pubmed/21602453">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1648 href="http://dx.doi.org/10.1210/jc.2011-0179">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d60749e1657 class=n-a></a>Cook DM, Yuen KC, Biller BM, <i> et al.</i>: American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. <i>Endocr Pract.</i> 2009; <b>15</b>(Suppl 2): 1–29. <a target=xrefwindow id=d60749e1668 href="http://www.ncbi.nlm.nih.gov/pubmed/20228036">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1671 href="http://dx.doi.org/10.4158/EP.15.S2.1">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d60749e1680 class=n-a></a>Ho KK,; 2007 GH Deficiency Consensus Workshop Participants: Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. <i>Eur J Endocrinol.</i> 2007; <b>157</b>(6): 695–700. <a target=xrefwindow id=d60749e1688 href="http://www.ncbi.nlm.nih.gov/pubmed/18057375">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1691 href="http://dx.doi.org/10.1530/EJE-07-0631">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d60749e1700 class=n-a></a>Melmed S: Idiopathic adult growth hormone deficiency. <i>J Clin Endocrinol Metab.</i> 2013; <b>98</b>(6): 2187–97. <a target=xrefwindow id=d60749e1708 href="http://www.ncbi.nlm.nih.gov/pubmed/23539718">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1711 href="http://dx.doi.org/10.1210/jc.2012-4012">Publisher Full Text </a> | <a target=xrefwindow id=d60749e1714 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3667267">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d60749e1723 class=n-a></a>Vance ML: Can growth hormone prevent aging? <i>N Engl J Med.</i> 2003; <b>348</b>(9): 779–80. <a target=xrefwindow id=d60749e1731 href="http://www.ncbi.nlm.nih.gov/pubmed/12606731">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1734 href="http://dx.doi.org/10.1056/NEJMp020186">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d60749e1744 class=n-a></a>Thorner MO: Statement by the Growth Hormone Research Society on the GH/IGF-I axis in extending health span. <i>J Gerontol A Biol Sci Med Sci.</i> 2009; <b>64</b>(10): 1039–44. <a target=xrefwindow id=d60749e1752 href="http://www.ncbi.nlm.nih.gov/pubmed/19587105">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1755 href="http://dx.doi.org/10.1093/gerona/glp091">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d60749e1764 class=n-a></a>Clemmons DR, Molitch M, Hoffman AR, <i> et al.</i>: Growth hormone should be used only for approved indications. <i>J Clin Endocrinol Metab.</i> 2014; <b>99</b>(2): 409–11. <a target=xrefwindow id=d60749e1775 href="http://www.ncbi.nlm.nih.gov/pubmed/24423315">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1778 href="http://dx.doi.org/10.1210/jc.2013-4187">Publisher Full Text </a> | <a target=xrefwindow id=d60749e1782 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5393472">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d60749e1791 class=n-a></a>Allen DB, Backeljauw P, Bidlingmaier M, <i> et al.</i>: GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. <i>Eur J Endocrinol.</i> 2016; <b>174</b>(2): P1–9. <a target=xrefwindow id=d60749e1802 href="http://www.ncbi.nlm.nih.gov/pubmed/26563978">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1805 href="http://dx.doi.org/10.1530/EJE-15-0873">Publisher Full Text </a> | <a target=xrefwindow id=d60749e1809 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4674592">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d60749e1818 class=n-a></a>Tanriverdi F, Kelestimur F: Classical and non-classical causes of GH deficiency in adults. <i>Best Pract Res Clin Endocrinol Metab.</i> 2017; <b>31</b>(1): 3–11. <a target=xrefwindow id=d60749e1826 href="http://www.ncbi.nlm.nih.gov/pubmed/28477730">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1829 href="http://dx.doi.org/10.1016/j.beem.2017.02.001">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d60749e1838 class=n-a></a>Tauber M, Moulin P, Pienkowski C, <i> et al.</i>: Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. <i>J Clin Endocrinol Metab.</i> 1997; <b>82</b>(2): 352–6. <a target=xrefwindow id=d60749e1849 href="http://www.ncbi.nlm.nih.gov/pubmed/9024217">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1852 href="http://dx.doi.org/10.1210/jcem.82.2.3726">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d60749e1861 class=n-a></a>Boguszewski CL, Lacerda CS, Lacerda Filho Ld, <i> et al.</i>: Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period. <i>Arq Bras Endocrinol Metabol.</i> 2013; <b>57</b>(9): 709–16. <a target=xrefwindow id=d60749e1872 href="http://www.ncbi.nlm.nih.gov/pubmed/24402016">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1875 href="http://dx.doi.org/10.1590/S0004-27302013000900006">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d60749e1885 class=n-a></a>Shalet SM: Partial growth hormone deficiency in adults; should we be looking for it? <i>Clin Endocrinol (Oxf).</i> 2010; <b>73</b>(4): 432–5. <a target=xrefwindow id=d60749e1893 href="http://www.ncbi.nlm.nih.gov/pubmed/20455893">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1896 href="http://dx.doi.org/10.1111/j.1365-2265.2010.03809.x">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d60749e1905 class=n-a></a>Yuen KC, Biller BM, Molitch ME, <i> et al.</i>: Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? <i>J Clin Endocrinol Metab.</i> 2009; <b>94</b>(8): 2702–7. <a target=xrefwindow id=d60749e1916 href="http://www.ncbi.nlm.nih.gov/pubmed/19509104">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1919 href="http://dx.doi.org/10.1210/jc.2009-0299">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d60749e1928 class=n-a></a>Boguszewski CL: Glucagon stimulation test: has its time come? <i>Endocrine.</i> 2017; <b>57</b>(3): 361–363. <a target=xrefwindow id=d60749e1936 href="http://www.ncbi.nlm.nih.gov/pubmed/28646378">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1939 href="http://dx.doi.org/10.1007/s12020-017-1356-8">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d60749e1948 class=n-a></a>Conceição FL, da Costa e Silva A, Leal Costa AJ, <i> et al.</i>: Glucagon stimulation test for the diagnosis of GH deficiency in adults. <i>J Endocrinol Invest.</i> 2003; <b>26</b>(11): 1065–70. <a target=xrefwindow id=d60749e1959 href="http://www.ncbi.nlm.nih.gov/pubmed/15008242">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1962 href="http://dx.doi.org/10.1007/BF03345251">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726161216"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e1971 class=n-a></a>Hamrahian AH, Yuen KC, Gordon MB, <i> et al.</i>: Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study. <i>Pituitary.</i> 2016; <b>19</b>(3): 332–41. <a target=xrefwindow id=d60749e1982 href="http://www.ncbi.nlm.nih.gov/pubmed/26897383">PubMed Abstract </a> | <a target=xrefwindow id=d60749e1985 href="http://dx.doi.org/10.1007/s11102-016-0712-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726161216">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726504095"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e1998 class=n-a></a>Yuen KC, Tritos NA, Samson SL, <i> et al.</i>: American Association Of Clinical Endocrinologists And American College Of Endocrinology Disease State Clinical Review: Update On Growth Hormone Stimulation Testing And Proposed Revised Cut-Point For The Glucagon Stimulation Test In The Diagnosis Of Adult Growth Hormone Deficiency. <i>Endocr Pract.</i> 2016; <b>22</b>(10): 1235–44. <a target=xrefwindow id=d60749e2009 href="http://www.ncbi.nlm.nih.gov/pubmed/27409821">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2012 href="http://dx.doi.org/10.4158/EP161407.DSCR">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726504095">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d60749e2026 class=n-a></a>Junnila RK, Strasburger CJ, Bidlingmaier M: Pitfalls of insulin-like growth factor-i and growth hormone assays. <i>Endocrinol Metab Clin North Am.</i> 2015; <b>44</b>(1): 27–34. <a target=xrefwindow id=d60749e2034 href="http://www.ncbi.nlm.nih.gov/pubmed/25732639">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2037 href="http://dx.doi.org/10.1016/j.ecl.2014.10.003">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d60749e2046 class=n-a></a>Brabant G, Krogh Rasmussen A, Biller BM, <i> et al.</i>: Clinical implications of residual growth hormone (GH) response to provocative testing in adults with severe GH deficiency. <i>J Clin Endocrinol Metab.</i> 2007; <b>92</b>(7): 2604–9. <a target=xrefwindow id=d60749e2057 href="http://www.ncbi.nlm.nih.gov/pubmed/17488801">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2060 href="http://dx.doi.org/10.1210/jc.2007-0153">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d60749e2069 class=n-a></a>Corneli G, Di Somma C, Baldelli R, <i> et al.</i>: The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. <i>Eur J Endocrinol.</i> 2005; <b>153</b>(2): 257–64. <a target=xrefwindow id=d60749e2080 href="http://www.ncbi.nlm.nih.gov/pubmed/16061832">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2083 href="http://dx.doi.org/10.1530/eje.1.01967">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726089624"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e2092 class=n-a></a>Wilson JR, Utz AL, Devin JK: Effects of gender, body weight, and blood glucose dynamics on the growth hormone response to the glucagon stimulation test in patients with pituitary disease. <i>Growth Horm IGF Res.</i> 2016; <b>26</b>: 24–31. <a target=xrefwindow id=d60749e2100 href="http://www.ncbi.nlm.nih.gov/pubmed/26774402">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2103 href="http://dx.doi.org/10.1016/j.ghir.2015.12.005">Publisher Full Text </a> | <a target=xrefwindow id=d60749e2106 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4716555">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726089624">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d60749e2119 class=n-a></a>Clayton PE, Cuneo RC, Juul A, <i> et al.</i>: Consensus statement on the management of the GH-treated adolescent in the transition to adult care. <i>Eur J Endocrinol.</i> 2005; <b>152</b>(2): 165–70. <a target=xrefwindow id=d60749e2130 href="http://www.ncbi.nlm.nih.gov/pubmed/15745921">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2133 href="http://dx.doi.org/10.1530/eje.1.01829">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d60749e2142 class=n-a></a>Maghnie M, Aimaretti G, Bellone S, <i> et al.</i>: Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. <i>Eur J Endocrinol.</i> 2005; <b>152</b>(4): 589–96. <a target=xrefwindow id=d60749e2153 href="http://www.ncbi.nlm.nih.gov/pubmed/15817915">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2156 href="http://dx.doi.org/10.1530/eje.1.01873">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d60749e2166 class=n-a></a>Dichtel LE, Yuen KC, Bredella MA, <i> et al.</i>: Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. <i>J Clin Endocrinol Metab.</i> 2014; <b>99</b>(12): 4712–9. <a target=xrefwindow id=d60749e2177 href="http://www.ncbi.nlm.nih.gov/pubmed/25210883">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2180 href="http://dx.doi.org/10.1210/jc.2014-2830">Publisher Full Text </a> | <a target=xrefwindow id=d60749e2184 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4255132">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d60749e2193 class=n-a></a>Clayton P, Gleeson H, Monson J, <i> et al.</i>: Growth hormone replacement throughout life: insights into age-related responses to treatment. <i>Growth Horm IGF Res.</i> 2007; <b>17</b>(5): 369–82. <a target=xrefwindow id=d60749e2204 href="http://www.ncbi.nlm.nih.gov/pubmed/17560153">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2207 href="http://dx.doi.org/10.1016/j.ghir.2007.04.010">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d60749e2216 class=n-a></a>Geffner ME: Growth hormone replacement therapy: transition from adolescence to adulthood. <i>J Clin Res Pediatr Endocrinol.</i> 2009; <b>1</b>(5): 205–8. <a target=xrefwindow id=d60749e2224 href="http://www.ncbi.nlm.nih.gov/pubmed/21274297">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2227 href="http://dx.doi.org/10.4274/jcrpe.v1i5.205">Publisher Full Text </a> | <a target=xrefwindow id=d60749e2230 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3005750">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d60749e2239 class=n-a></a>Lanes R, Boguszewski CL, Calzada R, <i> et al.</i>: Growth hormone deficiency: transition from adolescence to adulthood. Highlights from a Latin-American Serono Symposia International Foundation Conference. <i>J Pediatr Endocrinol Metab.</i> 2010; <b>23</b>(3): 225–33. <a target=xrefwindow id=d60749e2250 href="http://www.ncbi.nlm.nih.gov/pubmed/20480720">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2253 href="http://dx.doi.org/10.1515/JPEM.2010.23.3.225">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d60749e2262 class=n-a></a>Maison P, Griffin S, Nicoue-Beglah M, <i> et al.</i>: Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. <i>J Clin Endocrinol Metab.</i> 2004; <b>89</b>(5): 2192–9. <a target=xrefwindow id=d60749e2273 href="http://www.ncbi.nlm.nih.gov/pubmed/15126541">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2276 href="http://dx.doi.org/10.1210/jc.2003-030840">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d60749e2285 class=n-a></a>Widdowson WM, Gibney J: The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. <i>J Clin Endocrinol Metab.</i> 2008; <b>93</b>(11): 4413–7. <a target=xrefwindow id=d60749e2293 href="http://www.ncbi.nlm.nih.gov/pubmed/18697875">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2296 href="http://dx.doi.org/10.1210/jc.2008-1239">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718238703"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e2306 class=n-a></a>Barake M, Klibanski A, Tritos NA: Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. <i>J Clin Endocrinol Metab.</i> 2014; <b>99</b>(3): 852–60. <a target=xrefwindow id=d60749e2314 href="http://www.ncbi.nlm.nih.gov/pubmed/24423364">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2317 href="http://dx.doi.org/10.1210/jc.2013-3921">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718238703">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d60749e2330 class=n-a></a>Xue P, Wang Y, Yang J, <i> et al.</i>: Effects of growth hormone replacement therapy on bone mineral density in growth hormone deficient adults: a meta-analysis. <i>Int J Endocrinol.</i> 2013; <b>2013</b>: 216107. <a target=xrefwindow id=d60749e2341 href="http://www.ncbi.nlm.nih.gov/pubmed/23690770">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2344 href="http://dx.doi.org/10.1155/2013/216107">Publisher Full Text </a> | <a target=xrefwindow id=d60749e2348 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3652209">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d60749e2357 class=n-a></a>Bryant J, Loveman E, Chase D, <i> et al.</i>: Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation. <i>Health Technol Assess.</i> 2002; <b>6</b>(19): 1–106. <a target=xrefwindow id=d60749e2368 href="http://www.ncbi.nlm.nih.gov/pubmed/12583817">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2371 href="http://dx.doi.org/10.3310/hta6190">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718880170"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e2380 class=n-a></a>Mo D, Blum WF, Rosilio M, <i> et al.</i>: Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study. <i>J Clin Endocrinol Metab.</i> 2014; <b>99</b>(12): 4581–8. <a target=xrefwindow id=d60749e2391 href="http://www.ncbi.nlm.nih.gov/pubmed/25233155">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2394 href="http://dx.doi.org/10.1210/jc.2014-2892">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718880170">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726914981"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e2407 class=n-a></a>Elbornsson M, Horvath A, Götherström G, <i> et al.</i>: Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. <i>Eur J Endocrinol.</i> 2017; <b>176</b>(2): 99–109. <a target=xrefwindow id=d60749e2418 href="http://www.ncbi.nlm.nih.gov/pubmed/27803031">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2421 href="http://dx.doi.org/10.1530/EJE-16-0875">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726914981">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d60749e2434 class=n-a></a>Higham CE, Johannsson G, Shalet SM: Hypopituitarism. <i>Lancet.</i> 2016; <b>388</b>(10058): 2403–15. <a target=xrefwindow id=d60749e2442 href="http://www.ncbi.nlm.nih.gov/pubmed/27041067">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2445 href="http://dx.doi.org/10.1016/S0140-6736(16)30053-8">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726840765"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e2455 class=n-a></a>Fleseriu M, Hashim IA, Karavitaki N, <i> et al.</i>: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab.</i> 2016; <b>101</b>(11): 3888–921. <a target=xrefwindow id=d60749e2466 href="http://www.ncbi.nlm.nih.gov/pubmed/27736313">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2469 href="http://dx.doi.org/10.1210/jc.2016-2118">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726840765">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d60749e2482 class=n-a></a>Johannsson G, Bjarnason R, Bramnert M, <i> et al.</i>: The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. <i>J Clin Endocrinol Metab.</i> 1996; <b>81</b>(4): 1575–81. <a target=xrefwindow id=d60749e2493 href="http://www.ncbi.nlm.nih.gov/pubmed/8636370">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2496 href="http://dx.doi.org/10.1210/jcem.81.4.8636370">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d60749e2505 class=n-a></a>Ho KK, Gibney J, Johannsson G, <i> et al.</i>: Regulating of growth hormone sensitivity by sex steroids: implications for therapy. <i>Front Horm Res.</i> 2006; <b>35</b>: 115–28. <a target=xrefwindow id=d60749e2516 href="http://www.ncbi.nlm.nih.gov/pubmed/16809927">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2519 href="http://dx.doi.org/10.1159/000094314">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d60749e2528 class=n-a></a>Barbosa EJ, Koranyi J, Filipsson H, <i> et al.</i>: Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. <i>Eur J Endocrinol.</i> 2010; <b>162</b>(5): 869–78. <a target=xrefwindow id=d60749e2539 href="http://www.ncbi.nlm.nih.gov/pubmed/20145045">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2542 href="http://dx.doi.org/10.1530/EJE-09-0973">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d60749e2551 class=n-a></a>Barbosa EJ, Palming J, Glad CA, <i> et al.</i>: Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. <i>J Clin Endocrinol Metab.</i> 2009; <b>94</b>(2): 639–44. <a target=xrefwindow id=d60749e2562 href="http://www.ncbi.nlm.nih.gov/pubmed/19050057">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2565 href="http://dx.doi.org/10.1210/jc.2008-0323">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d60749e2574 class=n-a></a>Barbosa EJ, Glad CA, Nilsson AG, <i> et al.</i>: Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy. <i>Eur J Endocrinol.</i> 2012; <b>167</b>(3): 353–62. <a target=xrefwindow id=d60749e2585 href="http://www.ncbi.nlm.nih.gov/pubmed/22715478">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2588 href="http://dx.doi.org/10.1530/EJE-12-0263">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d60749e2598 class=n-a></a>Barbosa EJ, Glad CA, Nilsson AG, <i> et al.</i>: Extracellular water and blood pressure in adults with growth hormone (GH) deficiency: a genotype-phenotype association study. <i>PLoS One.</i> 2014; <b>9</b>(8): e105754. <a target=xrefwindow id=d60749e2609 href="http://www.ncbi.nlm.nih.gov/pubmed/25157616">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2612 href="http://dx.doi.org/10.1371/journal.pone.0105754">Publisher Full Text </a> | <a target=xrefwindow id=d60749e2616 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4144955">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d60749e2625 class=n-a></a>Glad CA, Barbosa EJ, Filipsson Nyström H, <i> et al.</i>: SNPs within the GH-signaling pathway are associated with the early IGF1 response to GH replacement therapy in GHD adults. <i>Eur J Endocrinol.</i> 2013; <b>170</b>(1): 101–7. <a target=xrefwindow id=d60749e2636 href="http://www.ncbi.nlm.nih.gov/pubmed/24114431">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2639 href="http://dx.doi.org/10.1530/EJE-13-0685">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d60749e2648 class=n-a></a>Andujar-Plata P, Fernandez-Rodriguez E, Quinteiro C, <i> et al.</i>: Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency. <i>Pituitary.</i> 2015; <b>18</b>(1): 101–7. <a target=xrefwindow id=d60749e2659 href="http://www.ncbi.nlm.nih.gov/pubmed/24710993">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2662 href="http://dx.doi.org/10.1007/s11102-014-0562-0">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d60749e2671 class=n-a></a>Moyes VJ, Walker DM, Owusu-Antwi S, <i> et al.</i>: d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults. <i>Clin Endocrinol (Oxf).</i> 2010; <b>72</b>(6): 807–13. <a target=xrefwindow id=d60749e2682 href="http://www.ncbi.nlm.nih.gov/pubmed/20039885">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2685 href="http://dx.doi.org/10.1111/j.1365-2265.2009.03768.x">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d60749e2694 class=n-a></a>Meyer S, Schaefer S, Stolk L, <i> et al.</i>: Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults. <i>Pharmacogenomics.</i> 2009; <b>10</b>(10): 1599–608. <a target=xrefwindow id=d60749e2705 href="http://www.ncbi.nlm.nih.gov/pubmed/19842933">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2708 href="http://dx.doi.org/10.2217/pgs.09.91">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d60749e2717 class=n-a></a>Adetunji OR, Blair JC, Javadpour M, <i> et al.</i>: Deletion of exon 3 in the growth hormone receptor gene in adults with growth hormone deficiency: comparison of symptomatic and asymptomatic patients. <i>Clin Endocrinol (Oxf).</i> 2010; <b>72</b>(3): 422–3. <a target=xrefwindow id=d60749e2728 href="http://www.ncbi.nlm.nih.gov/pubmed/19486024">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2731 href="http://dx.doi.org/10.1111/j.1365-2265.2009.03638.x">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d60749e2741 class=n-a></a>Adetunji OR, MacFarlane IA, Javadpour M, <i> et al.</i>: The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy. <i>Eur J Endocrinol.</i> 2009; <b>161</b>(4): 541–6. <a target=xrefwindow id=d60749e2752 href="http://www.ncbi.nlm.nih.gov/pubmed/19605543">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2755 href="http://dx.doi.org/10.1530/EJE-09-0405">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d60749e2764 class=n-a></a>van der Klaauw AA, van der Straaten T, Baak-Pablo R, <i> et al.</i>: Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. <i>J Clin Endocrinol Metab.</i> 2008; <b>93</b>(7): 2828–34. <a target=xrefwindow id=d60749e2775 href="http://www.ncbi.nlm.nih.gov/pubmed/18397980">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2778 href="http://dx.doi.org/10.1210/jc.2007-2728">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d60749e2787 class=n-a></a>Giavoli C, Ferrante E, Profka E, <i> et al.</i>: Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy. <i>Eur J Endocrinol.</i> 2010; <b>163</b>(3): 361–8. <a target=xrefwindow id=d60749e2798 href="http://www.ncbi.nlm.nih.gov/pubmed/20592127">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2801 href="http://dx.doi.org/10.1530/EJE-10-0317">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d60749e2810 class=n-a></a>Møller N, Jørgensen JO: Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. <i>Endocr Rev.</i> 2009; <b>30</b>(2): 152–77. <a target=xrefwindow id=d60749e2818 href="http://www.ncbi.nlm.nih.gov/pubmed/19240267">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2821 href="http://dx.doi.org/10.1210/er.2008-0027">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d60749e2830 class=n-a></a>Filipsson H, Johannsson G: GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. <i>Eur J Endocrinol.</i> 2009; <b>161 Suppl 1</b>: S85–95. <a target=xrefwindow id=d60749e2838 href="http://www.ncbi.nlm.nih.gov/pubmed/19684055">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2841 href="http://dx.doi.org/10.1530/EJE-09-0319">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d60749e2850 class=n-a></a>Boguszewski CL, Boguszewski MC, Kopchick JJ: Growth hormone, insulin-like growth factor system and carcinogenesis. <i>Endokrynol Pol.</i> 2016; <b>67</b>(4): 414–26. <a target=xrefwindow id=d60749e2858 href="http://www.ncbi.nlm.nih.gov/pubmed/27387246">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2861 href="http://dx.doi.org/10.5603/EP.a2016.0053">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d60749e2871 class=n-a></a>Pekic S, Stojanovic M, Popovic V: Controversies in the risk of neoplasia in GH deficiency. <i>Best Pract Res Clin Endocrinol Metab.</i> 2017; <b>31</b>(1): 35–47. <a target=xrefwindow id=d60749e2879 href="http://www.ncbi.nlm.nih.gov/pubmed/28477731">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2882 href="http://dx.doi.org/10.1016/j.beem.2017.02.004">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726872199"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e2891 class=n-a></a>Olsson DS, Trimpou P, Hallén T, <i> et al.</i>: Life expectancy in patients with pituitary adenoma receiving growth hormone replacement. <i>Eur J Endocrinol.</i> 2017; <b>176</b>(1): 67–75. <a target=xrefwindow id=d60749e2902 href="http://www.ncbi.nlm.nih.gov/pubmed/27770012">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2905 href="http://dx.doi.org/10.1530/EJE-16-0450">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726872199">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726956034"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e2918 class=n-a></a>Li Z, Zhou Q, Li Y, <i> et al.</i>: Growth hormone replacement therapy reduces risk of cancer in adult with growth hormone deficiency: A meta-analysis. <i>Oncotarget.</i> 2016; <b>7</b>(49): 81862–9. <a target=xrefwindow id=d60749e2929 href="http://www.ncbi.nlm.nih.gov/pubmed/27835910">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2932 href="http://dx.doi.org/10.18632/oncotarget.13251">Publisher Full Text </a> | <a target=xrefwindow id=d60749e2936 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5348436">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726956034">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727113476"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e2949 class=n-a></a>Felicetti F, Fortunati N, Arvat E, <i> et al.</i>: GH deficiency in adult survivors of childhood cancer. <i>Best Pract Res Clin Endocrinol Metab.</i> 2016; <b>30</b>(6): 795–804. <a target=xrefwindow id=d60749e2960 href="http://www.ncbi.nlm.nih.gov/pubmed/27974192">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2963 href="http://dx.doi.org/10.1016/j.beem.2016.11.007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727113476">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d60749e2976 class=n-a></a>Gasco V, Caputo M, Lanfranco F, <i> et al.</i>: Management of GH treatment in adult GH deficiency. <i>Best Pract Res Clin Endocrinol Metab.</i> 2017; <b>31</b>(1): 13–24. <a target=xrefwindow id=d60749e2987 href="http://www.ncbi.nlm.nih.gov/pubmed/28477728">PubMed Abstract </a> | <a target=xrefwindow id=d60749e2990 href="http://dx.doi.org/10.1016/j.beem.2017.03.001">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d60749e2999 class=n-a></a>Boguszewski CL, Meister LH, Zaninelli DC, <i> et al.</i>: One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. <i>Eur J Endocrinol.</i> 2005; <b>152</b>(1): 67–75. <a target=xrefwindow id=d60749e3010 href="http://www.ncbi.nlm.nih.gov/pubmed/15762189">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3013 href="http://dx.doi.org/10.1530/eje.1.01817">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d60749e3023 class=n-a></a>Alexopoulou O, Beguin C, De Nayer P, <i> et al.</i>: Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. <i>Eur J Endocrinol.</i> 2004; <b>150</b>(1): 1–8. <a target=xrefwindow id=d60749e3034 href="http://www.ncbi.nlm.nih.gov/pubmed/14713273">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3037 href="http://dx.doi.org/10.1530/eje.0.1500001">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d60749e3046 class=n-a></a>Behan LA, Monson JP, Agha A: The interaction between growth hormone and the thyroid axis in hypopituitary patients. <i>Clin Endocrinol (Oxf).</i> 2011; <b>74</b>(3): 281–8. <a target=xrefwindow id=d60749e3054 href="http://www.ncbi.nlm.nih.gov/pubmed/20455887">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3057 href="http://dx.doi.org/10.1111/j.1365-2265.2010.03815.x">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d60749e3066 class=n-a></a>Koltowska-Häggström M, Mattsson AF, Shalet SM: Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. <i>Eur J Endocrinol.</i> 2009; <b>161 Suppl 1</b>: S51–64. <a target=xrefwindow id=d60749e3074 href="http://www.ncbi.nlm.nih.gov/pubmed/19684056">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3077 href="http://dx.doi.org/10.1530/EJE-09-0266">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d60749e3086 class=n-a></a>Ribeiro-Oliveira A Jr, Mol SS, Twiss J, <i> et al.</i>: The brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation. <i>Arq Bras Endocrinol Metabol.</i> 2010; <b>54</b>(9): 833–41. <a target=xrefwindow id=d60749e3097 href="http://www.ncbi.nlm.nih.gov/pubmed/21340177">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3100 href="http://dx.doi.org/10.1590/S0004-27302010000900010">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d60749e3109 class=n-a></a>Høybye C, Cohen P, Hoffman AR, <i> et al.</i>: Status of long-acting-growth hormone preparations--2015. <i>Growth Horm IGF Res.</i> 2015; <b>25</b>(5): 201–6. <a target=xrefwindow id=d60749e3120 href="http://www.ncbi.nlm.nih.gov/pubmed/26187188">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3123 href="http://dx.doi.org/10.1016/j.ghir.2015.07.004">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d60749e3132 class=n-a></a>Christiansen JS, Backeljauw PF, Bidlingmaier M, <i> et al.</i>: Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. <i>Eur J Endocrinol.</i> 2016; <b>174</b>(6): C1–8. <a target=xrefwindow id=d60749e3143 href="http://www.ncbi.nlm.nih.gov/pubmed/27009113">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3146 href="http://dx.doi.org/10.1530/EJE-16-0111">Publisher Full Text </a> | <a target=xrefwindow id=d60749e3150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5081743">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d60749e3160 class=n-a></a>Hoffman AR, Biller BM, Cook D, <i> et al.</i>: Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. <i>J Clin Endocrinol Metab.</i> 2005; <b>90</b>(12): 6431–40. <a target=xrefwindow id=d60749e3171 href="http://www.ncbi.nlm.nih.gov/pubmed/16159930">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3174 href="http://dx.doi.org/10.1210/jc.2005-0928">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d60749e3183 class=n-a></a>Biller BM, Ji HJ, Ahn H, <i> et al.</i>: Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. <i>J Clin Endocrinol Metab.</i> 2011; <b>96</b>(6): 1718–26. <a target=xrefwindow id=d60749e3194 href="http://www.ncbi.nlm.nih.gov/pubmed/21411551">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3197 href="http://dx.doi.org/10.1210/jc.2010-2819">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d60749e3206 class=n-a></a>Biller BM, Ji H, Ahn H, <i> et al.</i>: 12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency. <i>Pituitary.</i> 2013; <b>16</b>(3): 311–8. <a target=xrefwindow id=d60749e3217 href="http://www.ncbi.nlm.nih.gov/pubmed/22915288">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3220 href="http://dx.doi.org/10.1007/s11102-012-0422-8">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d60749e3229 class=n-a></a>Gilchrist FJ, Murray RD, Shalet SM: The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. <i>Clin Endocrinol (Oxf).</i> 2002; <b>57</b>(3): 363–70. <a target=xrefwindow id=d60749e3237 href="http://www.ncbi.nlm.nih.gov/pubmed/12201829">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3240 href="http://dx.doi.org/10.1046/j.1365-2265.2002.01608.x">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d60749e3249 class=n-a></a>Arwert LI, Roos JC, Lips P, <i> et al.</i>: Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. <i>Clin Endocrinol (Oxf).</i> 2005; <b>63</b>(3): 310–6. <a target=xrefwindow id=d60749e3260 href="http://www.ncbi.nlm.nih.gov/pubmed/16117819">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3263 href="http://dx.doi.org/10.1111/j.1365-2265.2005.02343.x">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d60749e3272 class=n-a></a>Götherström G, Elbornsson M, Stibrant-Sunnerhagen K, <i> et al.</i>: Muscle strength in elderly adults with GH deficiency after 10 years of GH replacement. <i>Eur J Endocrinol.</i> 2010; <b>163</b>(2): 207–15. <a target=xrefwindow id=d60749e3283 href="http://www.ncbi.nlm.nih.gov/pubmed/20463152">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3286 href="http://dx.doi.org/10.1530/EJE-10-0009">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d60749e3296 class=n-a></a>Elbornsson M, Götherström G, Bosæus I, <i> et al.</i>: Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. <i>Eur J Endocrinol.</i> 2012; <b>166</b>(5): 787–95. <a target=xrefwindow id=d60749e3307 href="http://www.ncbi.nlm.nih.gov/pubmed/22318746">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3310 href="http://dx.doi.org/10.1530/EJE-11-1072">Publisher Full Text </a> | <a target=xrefwindow id=d60749e3314 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3341655">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d60749e3323 class=n-a></a>Appelman-Dijkstra NM, Claessen KM, Hamdy NA, <i> et al.</i>: Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. <i>Clin Endocrinol (Oxf).</i> 2014; <b>81</b>(5): 727–35. <a target=xrefwindow id=d60749e3334 href="http://www.ncbi.nlm.nih.gov/pubmed/24816144">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3337 href="http://dx.doi.org/10.1111/cen.12493">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726429846"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d60749e3346 class=n-a></a>Allo Miguel G, Serraclara Plá A, Partida Muñoz ML, <i> et al.</i>: Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center. <i>Ther Adv Endocrinol Metab.</i> 2016; <b>7</b>(3): 93–100. <a target=xrefwindow id=d60749e3357 href="http://www.ncbi.nlm.nih.gov/pubmed/27293538">PubMed Abstract </a> | <a target=xrefwindow id=d60749e3360 href="http://dx.doi.org/10.1177/2042018816643908">Publisher Full Text </a> | <a target=xrefwindow id=d60749e3364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4892402">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726429846">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 16 Nov 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2017&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2017&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Endocrine Division (SEMPR), Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil<br/> <p> <div class=margin-bottom> Cesar Luiz Boguszewski <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-2017/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 16 Nov 2017, 6:2017 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.12057.1">https://doi.org/10.12688/f1000research.12057.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Boguszewski CL. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=13044 data-id=12057 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12057.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-2017/v1/pdf?article_uuid=6b716b3e-6c5f-4a94-86d3-88fdeb968eb8" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.12057.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Boguszewski CL. Update on GH therapy in adults [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2017 (<a href="https://doi.org/10.12688/f1000research.12057.1" target=_blank>https://doi.org/10.12688/f1000research.12057.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=12057 id=mobile-track-article-signin-12057 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12057?target=/articles/6-2017"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13044 /> <input name=articleId type=hidden value=12057 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Roberto Salvatori</strong>, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Manuel Aguiar-Oliveira</strong>, Division of Endocrinology, Federal University of Sergipe, Brazil </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Gianluca Aimaretti</strong>, Endocrinology, Department of Experimental and Clinical Medicine, University A. Avogadro del Piemonte Orientale, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 16 Nov 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2017&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2017&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=27857-27769></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=27859-27770></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=27858-27768></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-2017/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>16 Nov 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Roberto Salvatori</strong>, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Manuel Aguiar-Oliveira</strong>, Division of Endocrinology, Federal University of Sergipe, Brazil </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Gianluca Aimaretti</strong>, Endocrinology, Department of Experimental and Clinical Medicine, University A. Avogadro del Piemonte Orientale, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-2017&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-2017/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Update on GH therapy in adults".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-2017/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-2017/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-2017/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Boguszewski CL');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-2017/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-2017",
            templates : {
                twitter : "Update on GH therapy in adults. Boguszewski CL, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-2017/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Update on GH therapy in adults", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Update on GH therapy in adults", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/12057/13044")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "13044");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "27768": 0,
                           "27769": 0,
                           "27770": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "f6f53c6c-6924-4846-b444-46736903fb29";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2017.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2017.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2017.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-2017.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-2017.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>